Letter to the Editor
An urticarial drug eruption caused by tofacitinib for alopecia universalis
Brent J. Doolan,
Corresponding Author
Brent J. Doolan
Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Correspondence
Brent J. Doolan, BSc, MBBS, MPH&TM, Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia.
Email: [email protected]
Search for more papers by this author William C. Cranwell,
William C. Cranwell
Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Search for more papers by this author George A. Varigos,
George A. Varigos
Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Search for more papers by this author Ryan De Cruz,
Ryan De Cruz
Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Search for more papers by this author
Brent J. Doolan,
Corresponding Author
Brent J. Doolan
Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Correspondence
Brent J. Doolan, BSc, MBBS, MPH&TM, Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia.
Email: [email protected]
Search for more papers by this author William C. Cranwell,
William C. Cranwell
Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Search for more papers by this author George A. Varigos,
George A. Varigos
Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Search for more papers by this author Ryan De Cruz,
Ryan De Cruz
Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Search for more papers by this author
First published: 12 April 2019
No abstract is available for this article.
CONFLICT OF INTERESTS
The authors declare that they have no financial or other conflicts of interest in relation to this research and its publication. There was no funding supplied from any source.
REFERENCES
- Cohen, S. B., Tanaka, Y., Mariette, X., Curtis, J. R., Lee, E. B., Nash, P., … Wollenhaupt, J. (2017). Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials. Annals of the Rheumatic Diseases, 76(7), 1253–1262. https://doi.org/10.1136/annrheumdis-2016-210457
- Damsky, W., & King, B. A. (2017). JAK inhibitors in dermatology. The promise of a new drug class. Journal of the American Academy of Dermatology, 76(4), 736–744. https://doi.org/10.1016/j.jaad.2016.12.005
- King, B., Lee, A. I., & Choi, J. (2017). Treatment of Hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib. The Journal of Investigative Dermatology, 13794, 951–954. https://doi.org/10.1016/j.jid.2016.10.044
- Kirshenbaum, A., Bai, Y., & Metcalfe, D. D. (2018). Effect of tofacitinib on IgE-mediated degranulation of LAD2 human mast cells and PGD2 production. The Journal of Allergy and Clinical Immunology, 141(2), AB275. https://doi.org/10.1016/j.jaci.2017.12.877
- Triyangkulsri, K., & Suchonwanit, P. (2018). Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Design, Development and Therapy, 12, 2323–2335. https://doi.org/10.2147/DDDT.S172638
